Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer

Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer

(2012) Hideo Inaji et al.   CANCER SCIENCE

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Aromatase Inhibitors by Structure-Guided Design

(2012) Debashis Ghosh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen Resistance

(2012) John Koren et al.   PLoS One

Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer

(2012) Quan Jiang et al.   ACS Medicinal Chemistry Letters

KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

(2011) Muralidharan Anbalagan et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis

(2011) Mohammad H Forouzanfar et al.   LANCET

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

(2010) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

(2010) A Ahmad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors

(2010) Roshani R. Patel et al.   EUROPEAN JOURNAL OF CANCER

Antitumor Agents. 272. Structure−Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues

(2010) Yizhou Dong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)

(2010) Karen J. Kieser et al.   JOURNAL OF MEDICINAL CHEMISTRY

Third-Generation SERMs May Face Uphill Battle

(2010) C. Schmidt   JNCI-Journal of the National Cancer Institute

Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women

(2010) A. Z. LaCroix et al.   JNCI-Journal of the National Cancer Institute

Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer

(2009) T. Saeki et al.   ANNALS OF ONCOLOGY

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

(2009) Monique J. Bijl et al.   BREAST CANCER RESEARCH AND TREATMENT

Progression and treatment of HER2-positive breast cancer

(2009) April Davoli et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

(2009) John F.R. Robertson et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Src in breast cancer

(2008) R. S. Finn   ANNALS OF ONCOLOGY

Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches

(2008) P. Rizzo et al.   CANCER RESEARCH

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer

(2007) O.E. Young et al.   EUROPEAN JOURNAL OF CANCER